Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact Read more →

Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials Read more →

Curium strikes up to $8B deal for radiopharma rival Lantheus Read more →